(Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary)) - 药物靶点：FGFR1 x FGFR2_专利_临床

概要

基本信息

药物类型

生长因子

别名

FGF-2

靶点

FGFR1 x FGFR2

作用机制

FGFR1刺激剂(成纤维细胞生长因子受体-1刺激剂)、FGFR2刺激剂(成纤维细胞生长因子受体-2刺激剂)

治疗领域

耳鼻咽喉疾病其他疾病口颌疾病

在研适应症-

非在研适应症

根分叉部缺损牙龈退缩牙周炎+ [1]

原研机构-

在研机构-

非在研机构

SVS Institute of Dental Sciences

NYU Langone Health

Massachusetts Eye & Ear Infirmary, Inc.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

2

项与 Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary) 相关的临床试验

NCT04960384 / Recruiting临床2期IIT

Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations

This study is a double blinded, placebo-controlled phase II study evaluating the efficacy of FGF-2 for the treatment of chronic non-healing tympanic membrane perforations (TMP). The documentation of TM closure will be the main efficacy outcome measure. Pretreatment photographs will document the area of the TM perforation and allow measurement of surface areas of the TMP for comparison of pre- and post-treatment. The study will be divided into two phases, the Randomized Treatment phase (part A), and the Unblinded Crossover phase (part B). In part A of the study, subjects will be randomized 1:1 (using simple randomization) to receive FGF-2 or placebo treatment up to 3 treatments. Subjects that fail three study treatments will move on to part B of the study. Subjects who received placebo in part A and failed three placebo treatments will crossover to receive unblinded FGF-2 for up to 3 treatments. Subjects who received FGF-2 in part A and failed three experimental treatments will not have additional FGF-2 treatment, and will move on to study follow up.

开始日期2022-05-27

申办/合作机构

NYU Langone Health

NCT02307916 / Completed临床2期IIT

Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations

A Phase II randomized trial will be initiated to evaluate closure of the perforated tympanic membrane as the primary measureable outcome. The goal is to determine the safety and efficacy of Fibroblast Growth Factor-2 (FGF-2) in the closure of chronic tympanic membrane perforations (TMP). If FGF-2 is topically applied for the treatment of chronic TMP in humans, it is hypothesized it will be safe, tolerable and effective for use as treatment for tympanic membrane perforation. A total of 60 subjects will be recruited.

开始日期2016-10-01

申办/合作机构

Massachusetts Eye & Ear Infirmary, Inc.

[+1]

100 项与 Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary) 相关的临床结果

登录后查看更多信息

100 项与 Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary) 相关的转化医学

登录后查看更多信息

100 项与 Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary) 相关的专利（医药）

登录后查看更多信息

239

项与 Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary) 相关的文献（医药）

2024-01-01·Iranian journal of basic medical sciences

All-trans retinoic acid and fibroblast growth factor-2 enhance the fertility rate and embryo development in polycystic ovary syndrome mouse model.

Article

作者: Rahimi-Madiseh, Mohammad ; Anjomshoa, Maryam ; Rezaei, Shohreh ; Deris, Fatemeh ; Darabi, Shahram ; Rezaie, Mohammad Jafar ; Bahreini, Narges ; Zamani, Saeed ; Rustamzadeh, Auob

ObjectivesPolycystic ovary syndrome (PCOS) causes a developmental arrest of antral follicles and disrupts oocyte maturation. Retinoic acid (RA) and Fibroblast Growth Factor-2 (FGF2) are effective in follicle growth, thus their effects on histopathology and in vitro fertility of oocytes were investigated in PCOS-induced mice.Materials and MethodsEighty female NMRI mice were randomly divided into 8 groups including 1-Normal mice, 2-PCOS mice without any treatment, 3-Normal mice treated with RA, 4-Normal mice treated with FGF2, 5-PCOS mice treated with RA, 6- PCOS mice treated with FGF2, 7- PCOS mice treated with RA and FGF2, and 8- Normal mice treated with RA and FGF2. Following PCOS induction, the mice were treated with intraperitoneal RA and FGF2 as a treatment. Then ovarian stimulation, for preparing the oocyte and embryo microscopic examinations was performed. After oocyte morphometry, through in vitro fertilization, the embryo formation was assessed. Data was analyzed by one-way ANOVA and Tukey tests.ResultsThe results showed simultaneous injection of RA and FGF2 into PCOS-induced mice increases antral follicles and corpus luteum, but decreases cystic follicles. Simultaneous injection of these two substances into healthy mice increases the pre-antral follicles and corpus luteum. Simultaneous injection of RA and FGF2 increases the number of embryos in both control and intervention groups.ConclusionIt can be concluded that RA and FGF2 increase the maturity of ovarian follicles, the number of two-celled embryos, and the number of grade-A embryos in mice with PCOS, which is more effective when these two substances are injected simultaneously.

2023-09-04·Cardiology in review

Cardiotoxicity of breast cancer chemotherapy.

Article

作者: Frishman, William H ; Roberts, Sacha A

Breast cancer is one of the leading causes of malignancy affecting women in the United States. Although many effective treatments are available, most come with notable side effects that providers and patients must take into consideration. Various classes of chemotherapeutic agents, including anthracyclines and human epidermal growth factor receptor-2 antagonists, are known to be toxic to myocardial tissue. In this review article, we discuss what is reported in the literature regarding the cardiotoxicity of these agents as well as how to monitor and prevent cardiac injury and dysfunction.

2023-08-01·Journal of periodontal research

The role of rhFGF-2 in periodontal defect bone fill: A systematic review of the literature.

Review

作者: Doufexi, Aikaterini-Elisavet ; Pouliou, Maria-Myrsini ; Fragkioudakis, Ioannis ; Batas, Leonidas

BACKGROUNDGrowth factors have been used with success in periodontal regeneration, especially in intrabony defects. Among those, the recombined form of fibroblast growth factor-2 (rhFGF-2) has been also examined.OBJECTIVETo address the outcomes of periodontal regeneration using rhFGF-2 alone or in combination with bone substitutes primarily in terms of Radiographic Bone Fill (RBF%) and secondary Probing Pocket Depth (PPD), and Probing Attachment Levels (PAL).MATERIAL AND METHODSA search in MEDLINE and EMBASE using the Ovid interface was conducted from 2000 up to and including the 12th of November 2022. Starting from the initially identified 1289 articles, 34 studies were selected for further analysis. Following the full-text screening, 7 of the 34 studies met the inclusion criteria and thus were included in the systematic review after assessing their quality according to the Newcastle-Ottawa scale (NOS). Clinical and radiographic results (bone gain, pocket depth, and clinical attachment level) after the application of FGF-2 alone or in combination with different carriers were studied in patients with intrabony defects of at least one wall and pocket depth greater than 4 mm.RESULTSPrimary outcomes: RBF% was higher in studies using a combination of rhFGF-2 and bone substitutes (74.6 ± 20.0%) compared to others using the specific growth factor alone or negative controls (22.7 ± 20.7%). In terms of secondary outcomes, the analysis failed to show an additional benefit from the use of the rhFGF-2 alone or in combination with bone substitutes.CONCLUSIONrhFGF-2 can improve RBF% in the treatment of periodontal defects, especially when it is used in combination with a bone substitute.

100 项与 Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
根分叉部缺损	临床2期	印度	SVS Institute of Dental Sciences	2019-05-01
牙龈退缩	临床2期	印度	SVS Institute of Dental Sciences	2019-05-01
牙周炎	临床2期	印度	SVS Institute of Dental Sciences	2019-05-01
鼓膜穿孔	临床2期	美国	Massachusetts Eye & Ear Infirmary, Inc.	2016-10-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02307916 (CTgov)	临床2期	鼓膜穿孔	57	FGF-2 (FGF-2)	選鏇衊鏇獵積醖顧網築(網獵遞鹹範鑰齋夢憲鹽) = 觸醖獵獵鬱範艱製淵蓋願遞網鹽壓淵築衊選壓 (夢鹽糧構網餘淵網顧觸, 窪選鹹築構範遞齋鏇齋 ~ 願積壓簾觸餘糧範鏇醖) 更多	-	2020-06-11
				Placebo (Placebo)	選鏇衊鏇獵積醖顧網築(網獵遞鹹範鑰齋夢憲鹽) = 蓋願簾願醖淵憲廠淵夢願遞網鹽壓淵築衊選壓 (夢鹽糧構網餘淵網顧觸, 願淵齋窪餘糧鏇構齋艱 ~ 範襯壓獵衊簾構範壓觸) 更多
ARVO2012	N/A	-	-	TGFβ1	餘壓蓋齋選膚鏇壓膚網(獵艱網衊醖憲願遞築窪) = 網糧艱齋糧鏇襯網憲膚鑰醖鏇觸夢襯鑰蓋鹹醖 (廠鬱鹽簾壓鹽衊網蓋壓 ) 更多	-	2012-03-01
				FGF2	餘壓蓋齋選膚鏇壓膚網(獵艱網衊醖憲願遞築窪) = 廠顧顧鑰艱積鑰襯範積鑰醖鏇觸夢襯鑰蓋鹹醖 (廠鬱鹽簾壓鹽衊網蓋壓 ) 更多
ARVO2004	N/A	-	-	RPCs with EGF and FGF-2	繭蓋膚夢繭膚積築範繭(鬱簾淵鏇範網鏇廠遞鏇) = 壓製觸遞繭衊醖憲顧壓廠艱齋構壓齋齋顧窪願 (製鏇鑰顧築淵構選醖淵 ) 更多	-	2004-05-01
				RPCs without EGF and FGF-2	(簾蓋襯醖鬱壓醖鏇選簾) = 餘鹽糧獵襯壓構鏇鬱膚襯憲鹹夢夢廠壓鏇糧艱 (夢遞選築顧築鑰餘鹽窪 )